Here are the Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Does hypercalcemia cause hypomagnesemia, icd 10 code for severe hypomagnesemia, severe hypomagnesemia icd 10, hypomagnesemia vs hypermagnesemia symptoms, hypokalemia hypomagnesemia and hypocalcemia, risk factors of hypomagnesemia.
Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report
Background: Although hypomagnesemia is common in type 2 diabetes, clinical presentations with severe hypomagnesemia are rare. A number of oral blood glucose-lowering medications can reduce serum magnesium concentrations, and several severe cases have been reported in the presence of marked glucagon-like peptide-1 receptor agonist (GLP-1RA)-associated gastrointestinal adverse effects. In the present case, an acute presentation with severe hypomagnesemia was likely due to polypharmacy including semaglutide, albeit with a delayed relationship to discontinuation of this GLP-1RA, due to nausea and vomiting. Case Report: A 73-year-old woman with type 2 diabetes treated with several oral medications known to reduce serum magnesium (metformin, gliclazide, sitagliptin, esomeprazole) presented after an unwitnessed collapse at home without premonitory symptoms. She had discontinued low-dose semaglutide (0.25 mg subcutaneous weekly) 2 weeks beforehand, and her gas trointestinal adverse effects had largely resolved. She was found to have an undetectable serum magnesium (<0.3 mmol/L) and hypocalcemia. She responded to electrolyte replacement and was discharged well 2 days later. Three weeks after discharge, her serum magnesium and calcium concentrations were within the reference range, on regular oral supplements of both minerals. She spontaneously reported her longstanding muscle cramps had resolved after discharge. Her clinical features and course suggested she had chronic unrecognized hypomagnesemia associated with polypharmacy that progressed to a clinically severe level, with a likely contribution from recent antecedent semaglutide use. Conclusions: Periodic monitoring of serum magnesium concentrations in at-risk individuals with type 2 diabetes is recommended, since the clinical presentation of severe hypomagnesemia can be sudden and without indicative warning symptoms. © Am J Case Rep, 2025.
Authors : Davis T.M.E.
Source : International Scientific Information, Inc.
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.12659/AJCR.946539 |
| ISSN | 19415923 |
| Volume | 26 |
You can download the article here
If You have any problem, contact us here